Addiction & Substance Use

From substance use disorders in physicians to new research on the efficacy of MDMA-assisted therapy for PTSD, here are highlights from the week in Psychiatric Times.

What is new in research on posttraumatic stress disorder?

Captagon tablets: how are they impacting the current state of world affairs?

Reviewing a year of CMEs in Psychiatric Times®

What is new in research on cannabis?

What neuromodulation can be used to specifically target nicotine users with schizophrenia? This research may tell us.

Deep brain stimulation for substance use disorders when everything else fails, the history of the ACNP, and more.

Research presented at the ACNP 2023 Annual Meeting shows that neuromodulation therapy cTBS could be a viable schizophrenia-specific intervention for nicotine use.

The experts weighed in on a wide variety of psychiatric issues for the November 2023 issue of Psychiatric Times.

From late-life treatment-resistant depression to the mental health benefits of gratitude, here are highlights from the week in Psychiatric Times.

In this CME, review the risks and clinical implications of intimate partner violence on women’s substance use and treatment.

Young men appear to be particularly susceptible to the effects of cannabis on schizophrenia.

What is new in research on SUDs?

“Epidemiological surveys have shown that gender gaps and alcohol consumption and alcohol-related harms are narrowing for women and men—such that alcohol is growing women’s health issue.”

An expert addresses some common concerns about the drug and some effective ways clinicians can initiate the treatment at the 2023 Annual Psychiatric Times™ World CME Conference.

What is new in research on schizophrenia?

Explore the relationship between cannabis use and psychosis.

From violence risk assessment in emergency departments to connections between bipolar disorder and substance use disorders, here are highlights from the week in Psychiatric Times.

An expert discusses the connections between the 2 highly comorbid diseases and some ways to effectively treat both diseases simultaneously.

What is new in research on psychiatric care for Latinx patient populations?

What is the association between cannabis use disorders and schizophrenia? Researchers used a nationwide register-based cohort study to investigate these associations.

Today is International Overdose Awareness Day!

The funds will be distributed over the course of 5 years to support preclinical through phase 2 studies.

From informed consent in treatment with psychedelics to an anti-fentanyl antibody that may reverse the signs of carfentanil overdose, here are highlights from the week in Psychiatric Times.